Figure 6
Diagnostic, Prognostic, and Chemotherapy Response Value of Serum CitH3 in CRC. (A) Serum CitH3 levels in healthy controls vs. CRC patients (Mann-Whitney U test; ****p < 0.0001). (B) ROC curves comparing diagnostic performance of CitH3, CEA, and CA19-9 (AUC: CitH3 = 0.745, CEA = 0.774, CA19-9 = 0.647). (C) ROC curves for 1-, 3-, and 5-year survival prediction using CitH3 (AUC: 0.721, 0.668, 0.840). (D) Kaplan-Meier survival analysis stratified by serum CitH3 (cutoff: 5.989 ng/mL; log-rank ***p = 0.00065). (E) Serum CitH3 levels in chemotherapy-sensitive (TRG 0–1; n = 8) vs. -insensitive (TRG 2–3; n = 22) patients (**p < 0.01). (F) Serum CitH3 levels after excluding metastatic cases (sensitive: n = 8; insensitive: n = 11; *p < 0.05).
